Welcome to our dedicated page for Cytomx Therapeutics news (Ticker: CTMX), a resource for investors and traders seeking the latest updates and insights on Cytomx Therapeutics stock.
CytomX Therapeutics develops oncology biologics built on its PROBODY therapeutic platform, which masks and conditionally activates antibody-based therapies in the tumor microenvironment. News about CTMX commonly covers clinical updates for varsetatug masetecan, or Varseta-M, an EpCAM PROBODY ADC studied in advanced colorectal cancer and other EpCAM-expressing tumors, as well as CX-801, a masked Interferon-alpha-2b program initially developed in advanced melanoma.
Company updates also address financial results, research and development spending, cash runway, equity financings, and collaboration activity with Amgen, Regeneron, and Moderna. Recurring pipeline coverage includes dose-expansion data, combination-study activity, regulatory interactions, and PROBODY platform applications such as bispecific immunotherapies and T-cell engagers.
CytomX Therapeutics reported its financial results for 2022 and outlined significant advancements in its therapeutic pipeline, including the ongoing Phase 1 study for CX-904, a T-cell engaging bispecific therapy, and anticipated IND filings for CX-2051 and CX-801 later this year. The company highlighted collaborations with Bristol Myers Squibb, Moderna, and Regeneron, aiming to bolster its strategy and funding. Financially, total revenue for 2022 rose to $53.2 million, up from $37.3 million in 2021. However, cash reserves decreased to $194 million at year-end. CytomX is prioritizing ongoing clinical studies and reassessing its CX-2029 program following AbbVie’s decision to terminate its collaboration.
CytomX Therapeutics (Nasdaq: CTMX) announced it will release its full year 2022 financial results on March 27, 2023, after U.S. market close. The company will follow up with a conference call at 5:00 p.m. ET to discuss the results. Investors can access the live webcast on the company’s website and are encouraged to register 10 minutes prior to the call. CytomX is focused on developing conditionally activated biologics for cancer treatment, with a robust pipeline including collaborations with major partners like AbbVie and Bristol Myers Squibb.
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX) announced CEO Sean McCarthy's participation in March investor conferences. He will speak at the Cowen 43rd Annual Health Care Conference on March 7, 2023, at 9:10 a.m. ET in Boston, MA, and at the Barclays Global Healthcare Conference on March 14, 2023, at 4:05 p.m. ET in Miami, FL. Live webcasts of these events will be available on CytomX's website. CytomX focuses on conditionally activated biologics for cancer treatment, with a diverse pipeline, including collaborations with AbbVie and Bristol Myers Squibb.
CytomX Therapeutics (CTMX) has achieved a significant milestone by progressing its first Probody® TCB clinical candidate in collaboration with Astellas, triggering a $5 million milestone payment. This marks an important step in their multi-target collaboration, where CytomX retains U.S. co-commercialization and economic rights for select programs. The CEO emphasized the potential of localized T-cell engaging therapies to revolutionize cancer treatment. CytomX is advancing a diverse pipeline of seven therapeutic candidates, including T-cell engaging bispecific antibodies and antibody-drug conjugates, further enhancing its position in the oncology market.
CytomX Therapeutics will present at the B. Riley Securities Virtual Annual Oncology Investor Conference on January 19, 2023, at 2:30 p.m. ET. The company's CEO, Sean McCarthy, will lead the presentation, which can be accessed via a live webcast on CytomX’s website, with an archived replay available for 30 days. CytomX specializes in conditionally activated biologics, focusing on innovative cancer treatments, supported by its Probody® technology platform. The company’s pipeline includes seven therapeutic candidates, collaborating with major partners like AbbVie and Amgen. For more information, visit www.cytomx.com.
CytomX Therapeutics (Nasdaq: CTMX) has announced encouraging results from its Phase 2 cohort expansion study of CX-2029, showing a 21% objective response rate in squamous esophageal cancer and a 10% response rate in squamous non-small cell lung cancer (sqNSCLC) among heavily pre-treated patients. The company is collaborating with Moderna to develop mRNA-based therapeutics and anticipates filing two INDs for new wholly owned programs in 2023. CytomX also plans to determine next steps for CX-2029 with AbbVie this year, while continuing research in T-cell bispecifics.
CytomX Therapeutics (NASDAQ: CTMX) and Moderna (NASDAQ: MRNA) have announced a collaboration to create mRNA-based therapeutics using CytomX's Probody® platform. CytomX will receive $35 million upfront, including $5 million for research funding, with potential future payments of up to $1.2 billion in development milestones and royalties on commercialized products. The partnership aims to develop conditionally activated therapies for various diseases, enhancing both companies' therapeutic pipelines.
CytomX Therapeutics (Nasdaq: CTMX) announced plans to share its 2023 pipeline priorities and provide a data update for the CX-2029 Phase 2 cohort expansion study on January 5, 2023. The updates will follow a conference call at 5:00 p.m. ET. CytomX, a clinical-stage oncology biopharmaceutical company, focuses on developing conditionally activated treatments through its Probody® technology. Its pipeline includes ADCs and T-cell engaging bispecific antibodies, with CX-2029 currently in development, showing promise for patients with squamous non-small cell lung cancer.
CytomX Therapeutics (Nasdaq: CTMX) will have its CEO, Sean McCarthy, present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 3:00 p.m. ET. Attendees can watch a live webcast on CytomX's website, and an archived replay will be available for 30 days post-event. The company specializes in conditionally activated oncology therapeutics and has a diverse pipeline including investigational therapies like CX-2029 and collaborations with AbbVie and Amgen. For further details, visit www.cytomx.com.
CytomX Therapeutics (CTMX) announced that Phase 2 data for CX-2009, an ADC targeting CD166, will be presented at the San Antonio Breast Cancer Symposium on December 8, 2022. The data focuses on praluzatamab ravtansine for advanced HR+/HER2- breast cancer and triple-negative breast cancer. Despite previous decisions not to advance the program without a partner, the research has provided valuable insights for future Probody therapeutic candidates. The poster session is scheduled for 7:00 am - 8:15 am CT, featuring Dr. Kathy Miller as the presenting author.